Table 1 List of ESC guidelines used for the analysis
Nr | Guideline keyword | Year of publication | Representation of CMR in the guideline | Class of recommendation | |||
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | I | IIa | IIb | III |
1 | Ventricular arrhythmias and sudden cardiac death [2] | 2022 | CMR mentioned in the guideline text and in 17 recommendations | 4 | 10 | 3 | 0 |
2 | Non-cardiac surgery: cardiovascular assessment [3] | 2022 | CMR mentioned in the guideline text and in 4 recommendations | 1 | 1 | 1 | 1 |
3 | Cardio-oncology [4] | 2022 | CMR mentioned in the guideline text and in 5 recommendations | 4 | 1 | 0 | 0 |
4 | Pulmonary hypertension [5] | 2022 | CMR mentioned in the guideline text and in 1 recommendation | 0 | 0 | 1 | 0 |
5 | Valvular heart disease [6] | 2021 | CMR mentioned in the guideline text | - | - | - | - |
6 | Prevention [7] | 2021 | CMR mentioned in the guideline text | - | - | - | - |
7 | Pacing [8] | 2021 | CMR mentioned in the guideline text and in 2 recommendations | 1 | 1 | 0 | 0 |
8 | Heart failure [9] | 2021 | CMR mentioned in the guideline text and in 4 recommendations | 2 | 1 | 1 | 0 |
9 | Sports [10] | 2020 | CMR mentioned in the guideline text and in 5 recommendations | 1 | 2 | 1 | 1 |
10 | NSTEMI [11] | 2020 | CMR mentioned in the guideline text and in 1 recommendation | 1 | 0 | 0 | 0 |
11 | Atrial fibrillation [12] | 2020 | CMR mentioned in the guideline text | – | – | – | – |
12 | Congenital heart disease [13] | 2020 | CMR mentioned in the guideline text and in 3 recommendations | 1 | 2 | 0 | 0 |
13 | Chronic coronary syndrome [14] | 2019 | CMR mentioned in the guideline text and in 10 recommendations | 4 | 1 | 3 | 2 |
14 | Diabetes [15] | 2019 | CMR mentioned in the guideline text and in 3 recommendations | 1 | 0 | 2 | 0 |
15 | Dyslipidaemias [16] | 2019 | CMR not mentioned in the guideline text | – | – | – | – |
16 | Pulmonary embolism [17] | 2019 | CMR mentioned in the guideline text and in 1 recommendation | 0 | 0 | 0 | 1 |
17 | Supraventricular tachycardia [18] | 2019 | CMR mentioned in the guideline text | – | – | – | – |
18 | Myocardial revascularization [19] | 2018 | CMR mentioned in the guideline text and in 4 recommendation | 0 | 1 | 3 | 0 |
19 | Arterial hypertension [20] | 2018 | CMR mentioned | – | – | – | – |
20 | Cardiovascular diseases in pregnancy [21] | 2018 | CMR mentioned in the guideline text and in 3 recommendations | 2 | 1 | 0 | 0 |
21 | Syncope [22] | 2018 | CMR mentioned in the guideline text | – | – | – | – |
22 | Peripheral artery disease [23] | 2017 | CMR mentioned in the guideline text and in 5 recommendations | 5 | 0 | 0 | 0 |
23 | STEMI [24] | 2017 | CMR mentioned in the guideline text and in 3 recommendations | 0 | 2 | 1 | 0 |
24 | Pericardial diseases [25] | 2015 | CMR mentioned in the guideline text and in 5 recommendations | 3 | 1 | 1 | 0 |
25 | Endocarditis [26] | 2015 | CMR mentioned in the guideline text | – | – | – | – |
26 | Hypertrophic cardiomyopathy [27] | 2014 | CMR mentioned in the guideline text and in 7 recommendations | 2 | 3 | 2 | 0 |
27 | Aortic diseases [28] | 2014 | CMR mentioned in the guideline text and in 9 recommendations | 8 | 1 | 0 | 0 |